Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Mouse of a Different Color: Presenilin Mutations Affect Melanin
13 January 2006. As the roster of substrates for the γ-secretase protease continues to swell, the presenilin (PS) proteins seem to be popping up everywhere. Now, Hui Zheng and colleagues from Baylor College of Medicine in Houston, Texas, report they’ve spotted PS in yet another, entirely new pathway. Their work, published December 29 in PNAS Early Edition, shows that γ-secretase is required for melanin synthesis in the eyes and skin, at least in mice. Their results show that in the absence of γ-secretase activity, the intracellular trafficking of the melanin-producing enzyme tyrosinase to melanosomes stops, preventing pigment production. Tyrosinase and several related melanosomal type I membrane proteins appear to be substrates for γ-secretase, and in mice, the presenilin 1 M157V familial Alzheimer disease mutation impairs melanin synthesis. With this study, Zheng et al. have uncovered several new substrates for the γ-secretase, and a new role for PS in intracellular protein transport.

The initial clue linking presenilins to melanin production has been staring researchers in the face for several years. In previous work, Zheng and colleagues attempted to rescue the embryonic lethal phenotype of PS1/PS2 double knockout mice by breeding in a human PS1 transgene whose expression was restricted to the central nervous system. The approach was partially successful, and rather than perishing as embryos, the animals at least survived to birth. They expired soon after, however, and displayed massively abnormal kidney development due to compromised Notch signaling in non-neural tissues (Wang et al., 2003).

In those experiments, the researchers found they could distinguish the rescued mice from their control littermates at a glance—the transgene recipients all had white eyes. In the new work, chasing the white eye phenotype led first author Runsheng Wang and colleagues directly to the melanin synthesis pathway. This black pigment is produced inside melanosomes, membrane-bound organelles that contain the enzyme tyrosinase, which catalyzes the rate-limiting step in the transformation of tyrosine into melanin. [If this sounds familiar, it is. Melanosomes recently grabbed the attention of AD researchers, who found them to be filled with an amyloid of the Pmel17 protein, the first physiological amyloid found in higher organisms (see ARF related news story)].

With no PS1 expression, the eyes of the rescue mice were morphologically normal, but lacked pigment granules in the retinal pigmented epithelium (RPE) cells. The researchers showed that the mice had normal levels of the tyrosinase and two associated proteins, but the tyrosinase was mislocalized. PS+ cells contained a small number of tyrosinase-containing vesicles located near the trans-Golgi network. In normal eye cells, these vesicles appear to shuttle tyrosinase from where it is made in the secretory pathway to nearby early-stage melanosomes. But in the PS-null cells, these small, tyrosinase-loaded vesicles accumulated, and could be seen all over the cell body. The same cells contained only early-stage melanosomes that failed to mature or produce melanin.

Successful melanin synthesis depends on PS in skin cells, as well. Blocking γ-secretase activity with the inhibitor DAPT caused skin melanocytes to behave like the PS-null cells: Melanin synthesis was blocked and melanosome maturation stalled.

For many γ-secretase substrates, inactivation of PS leads to accumulation of a C-terminal cleavage fragment. Tyrosinase, as a type I membrane protein, was a candidate substrate, and the researchers detected a 7 kDa C-terminal fragment in either in PS 1 -/- cells, or in cells treated with DAPT. A CTF was also detected for two other tyrosinase-associated, melanosome-targeted proteins after DAPT treatment, suggesting that all three proteins could be PS substrates.

But what about the effect of FAD mutations on melanin production? From previous work (Wang et al., 2004), Zheng and colleagues knew that animals carrying the M146V FAD allele displayed learning and neurogenesis phenotypes, but only when the wild-type PS1 allele was absent. To look at effects on pigment in vivo, they bred heterozygous PS1 knockouts with knock-ins bearing the M146V FAD mutation in the endogenous PS1 gene, all on a PS2 null background. The mice carrying only the FAD mutant gene (PS2-/-, PS1 M146V/-), had a distinctly lighter coat color than did mice with a wild-type PS1 gene (PS2-/-, PS1+/-). PS1 gene dosage also appeared to affect pigmentation, although to a lesser extent than the mutation. Thus, while there was no noticeable difference in coat color between wild-type mice (PS1+/+) and PS1 knockout heterozygotes (PS1+/-), visual inspection of tail skin pigmentation and biochemical measurements of melanin content revealed that the PS1+/- produced less melanin than did the PS1 wild-type, and the PS1 M146V/- produced the least.

The results of Wang et al. establish a new role for PS in protein trafficking to melanosomes, but the mechanistic details of this regulation remain to be worked out. The physiological significance of the cleavage of tyrosinase cleavage and related proteins by γ-secretase is likewise totally unknown. The systems developed by the investigators provide a good opportunity for future studies to untangle these issues and the role of FAD mutations in presenilin function.

With this new data, melanosome biosynthesis is now known to involve not only a novel amyloid, but also a presenilin. A coincidence? one might ask. Or is there a link between PS and the Pmel17 protein, the precursor to melanosome amyloid? According to Michael Marks of the University of Pennsylvania in Philadelphia, it is unlikely that PS plays a role in the processing of Pmel17. Zheng’s data showed that Pmel17 protein levels and immunostaining patterns were unaffected by PS deficiency. In addition, the PS-deficient cells generate relatively intact early-stage melanosomes, which also argues against an obligatory role of PS in Pmel17 amyloid generation, Marks notes.

In the end, getting out of melanosomes and back to AD, Wang et al. conclude, “These findings raise the intriguing possibility that a compromised post-Golgi vesicle transport may contribute to Alzheimer’s disease pathogenesis.”—Pat McCaffrey.

Reference:
Wang R, Tang P, Wang P, Boissy RE, Zheng H. Regulation of tyrosinase trafficking and processing by presenilins: Partial loss of function by familial Alzheimer's disease mutation. Proc Natl Acad Sci U S A. 2005 Dec 29; [Epub ahead of print] Abstract

 
Comments on News and Primary Papers
  Primary Papers: Regulation of tyrosinase trafficking and processing by presenilins: partial loss of function by familial Alzheimer's disease mutation.

Comment by:  Takaomi Saido, ARF Advisor
Submitted 8 January 2006  |  Permalink Posted 8 January 2006
  I recommend this paper

  Primary Papers: Regulation of tyrosinase trafficking and processing by presenilins: partial loss of function by familial Alzheimer's disease mutation.

Comment by:  Takaomi Saido
Submitted 8 January 2006  |  Permalink Posted 8 January 2006
  I recommend this paper

  Primary Papers: Regulation of tyrosinase trafficking and processing by presenilins: partial loss of function by familial Alzheimer's disease mutation.

Comment by:  Tommaso Russo, ARF Advisor
Submitted 9 January 2006  |  Permalink Posted 9 January 2006
  I recommend this paper

  Comment by:  Michael S. Marks
Submitted 16 January 2006  |  Permalink Posted 16 January 2006

The lack of pigmentation in the presenilin mutants is a very interesting and potentially very important finding. It raises the question of what the molecular basis for the dysfunctional melanosomes could be. While the appearance of tyrosinase cleavage fragments upon presenilin inhibition is a useful molecular marker, it is unclear how this relates to the trafficking defect observed; indeed, it would seem more likely to be a consequence of tyrosinase mistrafficking rather than a cause. Cleavage of a vesicle "cargo" protein would be unlikely to cause the accumulation of vesicles. Moreover, it is unclear how loss of presenilin proteolytic activity would lead to increased proteolytic cleavage of tyrosinase. Thus, the mechanistic link between presenilin activity and melanosome targeting remains to be solved.

While cleavage of the pigment cell-specific protein Pmel17 by a proprotein convertase is necessary for amyloidogenesis and formation of the fibrous melanosome matrix, to my knowledge there is no link between presenilins and Pmel17 trafficking or processing. Moreover, we know...  Read more


  Comment by:  John Trojanowski, ARF Advisor
Submitted 16 January 2006  |  Permalink Posted 16 January 2006

Remarkable advances in understanding the pathobiology and mechanisms of neurodegeneration in AD over the past 20 years have engendered realistic hopes for the discovery of more meaningful and effective new drugs to treat AD. Based on these advances, most targets of drug discovery for AD focus on gains of toxic functions by amyloid deposits in AD such as those formed by fibrillar species of tau and Aβ. There is intense interest in Aβ-focused drug discovery efforts; most attempt to block or reverse Aβ plaque formation, or eliminate excess accumulations of Aβ oligomers and fibrils or aggregates of these pathological forms of Aβ.

Nonetheless, the onset and progression of AD also could result from loss-of-function abnormalities affecting tau or Aβ. When these proteins misfold, oligomerize, and fibrilize to form amyloid filaments and aggregate, the theory goes, they are sequestered and unable to perform their normal functions. However, a detailed understanding of the normal functions of Aβ, its precursor protein, as well as the presenilins required for γ-secretase cleavage of Aβ...  Read more


  Comment by:  Jacob Mack
Submitted 18 January 2006  |  Permalink Posted 23 January 2006

I believe this reductionist finding will have important implications for future molecular research into melanin transport. This could thus lead ultimately to new clinical treatment modalities for deficient genetic pigment manufacture. However, this will not lead to a new way to fight the battle against A.D. We are nowhere near the ability to do genetic reprogramming on such a grand scale. The ramifications of genetic tinkering in the way that would be necessary to apply these research findings is more than 15 years away in my opinion.

View all comments by Jacob Mack
  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad